Type I Hypersensitivity Clinical Trial
Official title:
A DoubleBlind Phase 2b Study to Evaluate Safety & Efficacy of Different Doses of Tyrosine Adsorbed Birch+Hazel+Alder Pollen Allergoid With MPL® in Patients Sensitized to Birch, Hazel, Alder Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease. Tree MATA MPL has been developed to provide pre-seasonal specific immunotherapy for patients with an allergy to tree pollen (hay fever). The purpose of this double-blind Phase IIb study is to assess the tolerability and immunogenicity of different doses of Tree MATA MPL in volunteers allergic to birch, hazel and alder pollen.
Tree MATAMPL (tyrosine adsorbed tree pollen allergoid with monophosphoryl lipid A (MPL®)) has been developed to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross-reacting tree pollens that cause rhinitis and/or conjunctivitis with or without mild to moderate asthma. This was a phase IIb, double-blind, placebo-controlled study to assess the tolerability and immunogenicity of different doses of Tree MATA MPL in volunteers allergic to birch, hazel and alder pollen. Sixty eight (68) volunteers were randomly assigned to one of three active treatments or placebo to receive up to 4 subcutaneous injections of either increasing doses of Tree MATAMPL or Placebo over 7 day (+1 day) interval. The duration of the study from screening (Visit 1) to end of study (Visit 6, Post-Treatment Visit) was approximately 50 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00133159 -
Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen
|
Phase 2 | |
| Completed |
NCT00133146 -
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
|
Phase 2 | |
| Terminated |
NCT00387478 -
Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis
|
Phase 2 | |
| Completed |
NCT00414141 -
Efficacy and Safety/Tolerability of Grass MATA MPL
|
Phase 3 | |
| Completed |
NCT00258635 -
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
|
Phase 2 | |
| Completed |
NCT00325338 -
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
|
Phase 2 | |
| Withdrawn |
NCT00109759 -
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
|
Phase 1 | |
| Completed |
NCT00110786 -
Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy
|
Phase 2 | |
| Completed |
NCT00423787 -
Efficacy and Safety/Tolerability of Ragweed MATA MPL
|
Phase 3 | |
| Completed |
NCT00104390 -
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
|
Phase 1 | |
| Completed |
NCT00104377 -
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
|
Phase 2 | |
| Completed |
NCT00116285 -
Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
|
Phase 1 | |
| Completed |
NCT00113750 -
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
|
Phase 2 | |
| Completed |
NCT00118625 -
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
|
Phase 2 | |
| Completed |
NCT00241410 -
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
|
Phase 1 | |
| Completed |
NCT00107705 -
Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing
|
Phase 1 |